Pfizer have published a series of PYK2 inhibitors « Kinase News

Blogroll
Tags

AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
Providing a resource for information on kinase inhibitors

Pfizer have published a series of PYK2 inhibitors

Posted on October 14, 2008 by crimsoncanary

Pfizer have published a series of trifluoromethylpyrimidine proline-rich tyrosine kinase 2 (PYK2) inhibitors

Filed under: Uncategorized | Tagged: kinase, Pfizer, Preclinical, pyk2, Research

« Novartis publish series of MK2 inhibitors Piramal initate Phase I trial with CDK4 inhibitor P-1446A-05 »